Zacks.com on MSN2h
ODAC to Discuss Exelixis' Application for Cabometyx Label ExpansionExelixis, Inc. EXEL announced that its supplemental new drug application (sNDA) for cabozantinib will be discussed at an ...
22h
Millions of Americans would be eligible to have costly weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback